Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Technique Directs Immune Cells to Target Leukemia

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
Targeted immunotherapy technique directs the patient’s own immune system to attack cancer cells.

A type of targeted immunotherapy induced remission in adults with an aggressive form of leukemia that had relapsed in 5 patients. The early results of this ongoing trial highlight the potential of the approach.

Acute lymphoblastic leukemia (ALL) is cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. In patients with B-cell ALL, the marrow produces too many B lymphocytes, which make antibodies to help fight infection.

When adult patients with B-cell ALL have remission followed by relapse, the prognosis is poor. Standard treatment uses chemotherapy to kill cancer cells, followed by a transplant of bone marrow stem cells to replace blood-forming cells destroyed by the chemotherapy.

Targeted immunotherapy has proven effective against less aggressive B-cell tumors. This technique directs the patient’s own immune system to attack cancer cells.

The researchers first remove immune cells known as T cells from the patient. These cells are genetically modified to produce an artificial receptor that can latch onto B cells and trigger their destruction. The modified T cells are then infused back into the patient.

As the technique showed success in targeting other types of B-cell tumors, a team led by Drs. Michel Sadelain and Renier J. Brentjens at the Memorial Sloan-Kettering Cancer Center set out to test it in people with relapsed B-cell ALL.

The receptor they added to the patients’ T cells was a chimeric antigen receptor (CAR) designed to target a protein called CD19 found on the surface of B cells.

Their phase I clinical trial was funded in part by NIH's National Cancer Institute (NCI). Results appeared on March 20, 2013, in Science Translational Medicine.

The researchers found that all 5 of the patients who received the therapy were in complete remission within weeks of the CAR-modified T-cell infusion.

Three patients were able to receive bone marrow transplants 1 to 4 months after the cell transfer therapy and were still in remission up to 2 years later.

One patient was unable to receive a stem cell transplant after the targeted therapy and relapsed. Another died while in remission of complications likely unrelated to the therapy.

Overall, the therapy itself was well tolerated. Three of the patients developed fevers and 2 needed high-dose steroid therapy to treat inflammation triggered by the treatment.

“Patients with relapsed B-cell ALL resistant to chemotherapy have a particularly poor prognosis,” Brentjens says. “The ability of our approach to achieve complete remissions in all of these very sick patients is what makes these findings so remarkable and this novel therapy so promising.”

The researchers are now testing the CAR-modified T cells in several more patients. Further clinical trials have also been planned to test whether B-cell ALL patients would benefit from receiving this therapy earlier in the course of disease-either along with initial chemotherapy or during remission to help prevent relapse.

“We need to examine the effectiveness of this targeted immunotherapy in additional patients before it could potentially become a standard treatment for patients with relapsed B-cell ALL,” Brentjens says.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Wednesday, April 27, 2016
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Thursday, April 21, 2016
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Wednesday, April 20, 2016
Submissions Open for the Cancer Moonshot Program
NCI opens online platform to submit ideas about research for Cancer Moonshot.
Tuesday, April 19, 2016
NIH Awards Grants to Explore Vaccine Adjuvants
NIH awards six grants to explore how combination adjuvants improve vaccines.
Wednesday, April 06, 2016
Experimental Vaccine Protects Against Dengue Virus
An experimental dengue vaccine protected all the volunteers who received it from infection with a live dengue virus.
Wednesday, March 30, 2016
Experimental Ebola Antibody Protects Monkeys
Antibody isolated from Ebola survivor can advance to clinical trials.
Friday, February 26, 2016
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Friday, January 15, 2016
In Uveitis, Bacteria in Gut May Instruct Immune Cells to Attack the Eye
NIH scientists propose novel mechanism to explain autoimmune uveitis.
Wednesday, August 19, 2015
Novel Mechanism to Explain Autoimmune Uveitis Proposed
A new study on mice suggests that bacteria in the gut may provide a kind of training ground for immune cells to attack the eye.
Wednesday, August 19, 2015
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Tuesday, July 21, 2015
Starting Antiretroviral Treatment Early Improves Outcomes for HIV-infected Individuals
NIH-funded trial results likely will impact global treatment guidelines.
Thursday, May 28, 2015
For Most Children with HIV and Low Immune Cell Count, Cells Rebound After Treatment
NIH-funded study finds T-cell level returns to normal with time.
Saturday, March 28, 2015
Strengthening the Immune System’s Fight Against Brain Cancer
NIH-funded research suggests novel way to improve vaccine efficacy in brain tumors.
Friday, March 20, 2015
Autoimmune Disease Super-Regulators Uncovered
Scientists discovered key genetic switches, called super-enhancers, involved in regulating the human immune system.
Tuesday, March 17, 2015
Scientific News
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Gut Microbiomes Of Infants Have An Impact On Autoimmunity
Exposure to pathogens early in life is beneficial to the education and development of the human immune system.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Reduced Immune Response Causes Flu Deaths in Older Adults
Yale study suggests that immune response to flu causes death in older people, not the virus.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!